Although a high expression level of AR has been associated with increased survival of ER+ BCa patients, the Richer group found that inhibition of AR by enzalutamide (ENZ) (a second generation antiandrogen) decreased BCa cell proliferation and tumor size (D’Amato et al. 2016). The gene discussed is AR; the disease is neoplasm.